The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Durvalumab after Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer
Open accessAbstract
BACKGROUND: Adjuvant therapy with durvalumab, with or without tremelimumab, may have efficacy in patients with limited-stage small-cell lung cancer who do not have disease progression after standard concurrent platinum-based chemoradiotherapy. METHODS: In a phase 3, double-blind, randomized, placebo-controlled trial, we assigned patients to receive durvalumab at a dose of 1500 mg, durvalumab (1500 mg) plus tremelimumab at a dose of 75 mg (four doses only), or placebo every 4 weeks for up to 24 months. Randomization was stratified according to disease stage (I or II vs. III) and receipt of prophylactic cranial irradiation (yes vs. no). Results of the first planned interim analysis of the two primary end points of overall survival and progression-free survival (assessed on the basis of blinded independent central review according to the Response Evaluation Criteria in Solid Tumors, version 1.1) with durvalumab as compared with placebo (data cutoff date, January 15, 2024) are reported; results in the durvalumab-tremelimumab group remain blinded. RESULTS: A total of 264 patients were assigned to the durvalumab group, 200 to the durvalumab-tremelimumab group, and 266 to the placebo group. Durvalumab therapy led to significantly longer overall survival than placebo (median, 55.9 months [95% confidence interval {CI}, 37.3 to not reached] vs. 33.4 months [95% CI, 25.5 to 39.9]; hazard ratio for death, 0.73; 98.321% CI, 0.54 to 0.98; P = 0.01), as well as to significantly longer progression-free survival (median 16.6 months [95% CI, 10.2 to 28.2] vs. 9.2 months [95% CI, 7.4 to 12.9]; hazard ratio for progression or death, 0.76; 97.195% CI, 0.59 to 0.98; P = 0.02). The incidence of adverse events with a maximum grade of 3 or 4 was 24.4% among patients receiving durvalumab and 24.2% among patients receiving placebo; adverse events led to discontinuation in 16.4% and 10.6% of the patients, respectively, and led to death in 2.7% and 1.9%. Pneumonitis or radiation pneumonitis with a maximum grade of 3 or 4 occurred in 3.1% of the patients in the durvalumab group and in 2.6% of those in the placebo group. CONCLUSIONS: Adjuvant therapy with durvalumab led to significantly longer overall survival and progression-free survival than placebo among patients with limited-stage small-cell lung cancer. (Funded by AstraZeneca; ADRIATIC ClinicalTrials.gov number, NCT03703297.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Durvalumab after chemoradiotherapy in stage III non–small-cell lung cancer
Antonia, S. J., Villegas, A., Daniel, D., Vicente, D., Murakami, S., Hui, R., Yokoi, T., Chiappori, A., Lee, K. H., de Wit, M., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1709937 · Cited by 4,593
Self-citationFirst-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer
Horn, L., Mansfield, A. S., Szczęsna, A., Havel, L., Krzakowski, M., Hochmair, M. J., Huemer, F., Losonczy, G., Johnson, M. L., Nishio, M., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1809064 · Cited by 3,586
Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC
Antonia, S. J., Villegas, A., Daniel, D., Vicente, D., Murakami, S., Hui, R., Kurata, T., Chiappori, A., Lee, K. H., de Wit, M., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1809697 · Cited by 2,798
Self-citationPaz-Ares, L., Dvorkin, M., Chen, Y., Reinmuth, N., Hotta, K., Trukhin, D., Statsenko, G., Hochmair, M. J., Özgüroğlu, M., Ji, J. H., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(19)32222-6 · Cited by 2,298
Self-citationTurrisi, A. T., Kim, K., Blum, R., Sause, W. T., Livingston, R. B., Komaki, R., Wagner, H., Aisner, S., & Johnson, D. H. (1999) · New England Journal of Medicine · doi:10.1056/nejm199901283400403 · Cited by 1,506
Spigel, D. R., Faivre-Finn, C., Gray, J. E., Vicente, D., Planchard, D., Paz-Ares, L., Vansteenkiste, J. F., Garassino, M. C., Hui, R., Quantin, X., et al. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.21.01308 · Cited by 1,445
Self-citationGay, C. M., Stewart, C. A., Park, E. M., Diao, L., Groves, S. M., Heeke, S., Nabet, B. Y., Fujimoto, J., Solis, L. M., Lu, W., et al. (2021) · Cancer Cell · doi:10.1016/j.ccell.2020.12.014 · Cited by 962
Self-citationSmall cell lung cancer: Where do we go from here?
Byers, L. A., & Rudin, C. M. (2015) · Cancer · doi:10.1002/cncr.29098 · Cited by 636
Small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up☆
Dingemans, A.-M. C., Früh, M., Ardizzoni, A., Besse, B., Faivre-Finn, C., Hendriks, L. E., Lantuejoul, S., Peters, S., Reguart, N., Rudin, C. M., et al. (2021) · Annals of Oncology · doi:10.1016/j.annonc.2021.03.207 · Cited by 626
Faivre-Finn, C., Snee, M., Ashcroft, L., Appel, W., Barlesi, F., Bhatnagar, A., Bezjak, A., Cardenal, F., Fournel, P., Harden, S., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30318-2 · Cited by 592
Small Cell Lung Cancer, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology
Ganti, A. K. P., Loo, B. W., Bassetti, M., Blakely, C., Chiang, A., D'Amico, T. A., D'Avella, C., Dowlati, A., Downey, R. J., Edelman, M., et al. (2021) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2021.0058 · Cited by 486
Identification and Characterization of MEDI4736, an Antagonistic Anti–PD-L1 Monoclonal Antibody
Stewart, R., Morrow, M., Hammond, S. A., Mulgrew, K., Marcus, D., Poon, E., Watkins, A., Mullins, S., Chodorge, M., Andrews, J., et al. (2015) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-14-0191 · Cited by 409
Paz-Ares, L., Chen, Y., Reinmuth, N., Hotta, K., Trukhin, D., Statsenko, G., Hochmair, M. J., Özgüroğlu, M., Ji, J. H., Garassino, M. C., et al. (2022) · ESMO Open · doi:10.1016/j.esmoop.2022.100408 · Cited by 346
Self-citationGiaccone, G., Debruyne, C., Felip, E., Chapman, P. B., Grant, S. C., Millward, M., Thiberville, L., D'addario, G., Coens, C., Rome, L. S., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.17.186 · Cited by 223
Peters, S., Pujol, J.-L., Dafni, U. G., Dómine, M., Popat, S., Reck, M., Andrade, J., Becker‐Commissaris, A., Moro‐Sibilot, D., Fontecedro, A. C., et al. (2021) · Annals of Oncology · doi:10.1016/j.annonc.2021.09.011 · Cited by 137
van den Ende, T., van den Boorn, H. G., Hoonhout, N. M., van Etten‐Jamaludin, F. S., Meijer, S. L., Derks, S., de Gruijl, T. D., Bijlsma, M. F., van Oijen, M. G. H., & van Laarhoven, H. W. M. (2020) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2020.188386 · Cited by 131
New Advances in the Second-Line Treatment of Small Cell Lung Cancer
Hurwitz, J. L., McCoy, F. P. G., Scullin, P., & Fennell, D. A. (2009) · The Oncologist · doi:10.1634/theoncologist.2009-0026 · Cited by 117
Bogart, J. A., Wang, X., Masters, G. A., Gao, J., Komaki, R. R., Gaspar, L. E., Heymach, J. V., Bonner, J. A., Kuzma, C. S., Waqar, S. N., et al. (2023) · Journal of Clinical Oncology · doi:10.1200/jco.22.01359 · Cited by 111
Senan, S., Okamoto, I., Lee, G., Chen, Y., Niho, S., Mak, G., Yao, W., Shire, N. J., Jiang, H., & Cho, B. C. (2019) · Clinical Lung Cancer · doi:10.1016/j.cllc.2019.12.006 · Cited by 81
Self-citationProgress in the management of limited‐stage small cell lung cancer
Amini, A., Byers, L. A., Welsh, J. W., & Komaki, R. U. (2013) · Cancer · doi:10.1002/cncr.28505 · Cited by 60
Caliman, E., Fancelli, S., Petroni, G., Michelet, M. R. G., Cosso, F., Ottanelli, C., Mazzoni, F., Voltolini, L., Pillozzi, S., & Antonuzzo, L. (2022) · Lung Cancer · doi:10.1016/j.lungcan.2022.11.014 · Cited by 59
García-Campelo, R., Sullivan, I., Arriola, E., Insa, A., Juan, Ó., Cruz‐Castellanos, P., Morán, T., Reguart, N., Zugazagoitia, J., & Dómine, M. (2023) · Clinical & Translational Oncology · doi:10.1007/s12094-023-03216-3 · Cited by 47
Tarhini, A. A., & Kirkwood, J. M. (2008) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.8.10.1583 · Cited by 44
Comparison of Carboplatin With Cisplatin in Small Cell Lung Cancer in US Veterans
Azar, I. H., Yazdanpanah, O., Jang, H., Austin, A., Kim, S., Chi, J., Alkassis, S., Saha, B. K., Chopra, A., Neu, K., et al. (2022) · JAMA Network Open · doi:10.1001/jamanetworkopen.2022.37699 · Cited by 42
Kuang, Y., Pierce, C. M., Chang, H., Sosinsky, A. Z., Deitz, A. C., Keller, S. M., Samkari, A., & Uyei, J. (2022) · Lung Cancer · doi:10.1016/j.lungcan.2022.06.005 · Cited by 28
Systemic therapy for limited stage small cell lung carcinoma
Noronha, V., Sekhar, A., Patil, V. M., Menon, N. S., Joshi, A., Kapoor, A., & Prabhash, K. (2020) · Journal of Thoracic Disease · doi:10.21037/jtd-2019-sclc-11 · Cited by 25
Rimner, A., Lai, W.-C. V., Califano, R., Jabbour, S. K., Rudin, C. M., Finn, C. F., Cho, B. C., Kato, T., Yu, J., Chafin, W., et al. (2022) · Clinical Lung Cancer · doi:10.1016/j.cllc.2022.04.005 · Cited by 20
Self-citationPatterns of Relapse in Small Cell Lung Cancer: Competing Risks of Thoracic versus CNS Relapse
Ellis, P. M., Swaminath, A., & Pond, G. R. (2021) · Current Oncology · doi:10.3390/curroncol28040243 · Cited by 18
Zhao, S., Chen, K., Shi, X., Sun, J., Fang, W., Huang, Y., & Zhang, L. (2023) · Clinical Lung Cancer · doi:10.1016/j.cllc.2023.06.009 · Cited by 4
Dawe, D. E., Rittberg, R., Syed, I. A., Shanahan, M. K., Moldaver, D., Bucher, O., Galloway, K., Reynolds, K., Paul, J. T., Harlos, C. H., et al. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1191920 · Cited by 2
Cited by
Hendriks, L. E. L., Remon, J., Faivre-Finn, C., Garassino, M. C., Heymach, J. V., Kerr, K. M., Tan, D. S. W., Veronesi, G., & Reck, M. (2024) · Nature Reviews Disease Primers · doi:10.1038/s41572-024-00551-9 · Cited by 568
Metadata
- Authors
- Cheng, Y., Spigel, D. R., Cho, B. C., Laktionov, K. K., Fang, J., Chen, Y., Zenke, Y., Lee, K. H., Wang, Q., Navarro, A., Bernabe, R., Buchmeier, E. L., Chang, J. W.-C., Shiraishi, Y., Goksu, S. S., Badzio, A., Shi, A., Daniel, D. B., Hoa, N. T. T., Zemanova, M., Mann, H., Gowda, H., Jiang, H., & Senan, S.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2024-10-10
- Volume
- 391
- Issue
- 14
- Pages
- 1313-1327
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W4402519167
- Cited by
- 358
- References
- 30
- FWCI
- 54.79
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.